Valuation : Caplin Point Laboratories Ltd

Market Cap 214B 2.26B 1.95B 1.83B 1.67B 3.13B 3.14B 21.61B 8.39B 110B 8.49B 8.3B 353B P/E 2027 *
29.4x
P/E 2028 * 25.4x
Enterprise Value 214B 2.26B 1.95B 1.83B 1.67B 3.13B 3.14B 21.61B 8.39B 110B 8.49B 8.3B 353B EV / Sales 2027 *
8.52x
EV / Sales 2028 * 7.54x
Free-Float
26.56%
Yield 2027 *
0.14%
Yield 2028 * 0.14%
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%-1.09%+19.16%+67.77% 48.26B
-1.72%-1.15%+45.80%+117.34% 40.5B
-0.70%-2.70%-10.84%+11.79% 11.85B
-2.01%-5.96%+10.47%+76.64% 11.83B
+2.31%0.00%+26.67%+153.33% 9.36B
+0.08%-4.11%+24.83%+43.80% 7.5B
-1.67%-0.35%+41.04%-11.59% 7.37B
-0.89%-3.09%+18.78%+207.82% 7.28B
-0.16%-2.36%-46.14%+16.28% 5.19B
Average -0.63%-2.09%+14.42%+75.91% 16.57B
Weighted average by Cap. -0.95%-1.71%+22.87%+82.78%

Financials

2027 *2028 *
Net sales 25.07B 265M 229M 215M 196M 367M 368M 2.54B 985M 12.86B 996M 975M 41.43B 28.34B 300M 258M 243M 222M 415M 416M 2.87B 1.11B 14.54B 1.13B 1.1B 46.82B
Net income 7.26B 76.89M 66.22M 62.23M 56.89M 106M 107M 735M 285M 3.73B 289M 282M 12B 8.41B 89.03M 76.67M 72.06M 65.87M 123M 124M 851M 330M 4.31B 334M 327M 13.9B
Net Debt - -
Logo Caplin Point Laboratories Ltd
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-